420 with CNW — Marijuana Rescheduling Likely to Reduce Barriers to Research

The Biden administration’s move to reclassify cannabis as a less hazardous substance is anticipated to ease some of the limitations on research. However, experts caution that while the change will alleviate certain restrictions, it won’t eliminate all of them. Additionally, it may not necessarily reduce the potential risks associated with cannabis or enhance users’ understanding of those risks.

Currently, cannabis is categorized as a Schedule I substance, indicating it is deemed to have a high abuse potential and no recognized medical value. The proposed shift by the Biden administration aims to move cannabis to Schedule III, acknowledging its medical benefits to some extent.

This adjustment is significant as the Schedule I classification imposes stringent regulations that hinder scientific research on cannabis, despite its increasing availability due to changes in state laws. These regulations encompass various aspects such as reporting, storage and security requirements, governed by entities such as the Food and Drug Administration (FDA), the U.S. Drug Enforcement Administration (DEA), local authorities and the Institutional Review Board.

Neuroscientist Staci Gruber of Harvard Medical School and McLean Hospital draws attention to the onerous procedures that researchers must go through, including registering with the DEA and obtaining federal and state permits to perform studies on cannabis.

According to advocates, reclassifying the drug to Schedule III, alongside drugs such as Tylenol and ketamine, will be a significant change that could affect attitudes and viewpoints on the study of drugs in different categories. Gruber sees this change as particularly beneficial for aspiring researchers who will no longer require a Schedule I license, thus facilitating their entry into the field.

Similarly, Dr. Andrew Monte, associate director of Rocky Mountain Poison and Drug Safety, believes that the reclassification will foster more research on the therapeutic benefits and potential risks of marijuana, thereby enhancing the quality of research outcomes.

However, despite the reclassification, Gruber notes that the availability of marijuana for research purposes may not significantly increase. Historically, researchers were limited to obtaining cannabis from a single source: the University of Mississippi. Although the DEA has started approving additional sources since 2021, the accessibility of these sources remains limited, hindering researchers’ ability to study the products commonly used by patients and consumers.

Moreover, there is a lack of comprehensive information regarding the composition of marijuana products available on the market today. Studies suggest that the current THC levels, the primary psychoactive component in cannabis, are substantially higher than in previous decades, posing greater health risks.

Monte warns against overlooking the health risks associated with cannabis, despite its reclassification. He and his colleagues have observed various adverse effects in individuals, such as intoxication and cyclic vomiting syndrome, as well as psychiatric symptoms, including psychosis, leading to hospital visits. Despite the reclassification, addressing these risks requires ongoing surveillance and research efforts, which the reclassification alone may not fulfill.

When the DEA finally announces its cannabis rescheduling decision, entities such as Astrotech Corp. (NASDAQ: ASTC) could see new opportunities for business as their testing equipment starts attracting more interest from the marijuana research community.

NOTE TO INVESTORS: The latest news and updates relating to Astrotech Corp. (NASDAQ: ASTC) are available in the company’s newsroom at https://cnw.fm/ASTC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Archives

Select A Month
  • November 2026
  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • July 2024
  • June 2024
  • May 2024
  • April 2024
  • March 2024
  • February 2024
  • January 2024
  • December 2023
  • November 2023
  • October 2023
  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • September 2016
  • August 2016
  • July 2016
  • Official NewsWire Relationships

    Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

    CannabisNewsWire Currently Accepts

    Bitcoin

    Bitcoin

    Bitcoin Cash

    Bitcoin Cash

    Doge Coin

    Dogecoin

    Ethereum

    Ethereum

    Litecoin

    Litecoin

    USD Coin

    USD Coin

    Contact us: 512.354.7000